AI Powered Animal Diagnostics
Leveraging AI to provide veterinarians with more accurate and affordable diagnostics.
Key people at Moichor.
Moichor was founded in 2019 by Shevy Karbasi (Founder) and Thanh Le (Founder) and Matthew Chen (Founder).
Moichor was founded in 2019 by Shevy Karbasi (Founder) and Thanh Le (Founder) and Matthew Chen (Founder).
Key people at Moichor.
Moichor is an AI-powered animal diagnostics company founded in 2019 that develops advanced veterinary diagnostic tools to support veterinarians with fast, accurate, and affordable testing solutions. Its flagship product, Pathview, is an in-clinic hematology and cytology system that delivers pathologist-level preliminary results in as little as 15 minutes for any animal species, including exotic pets. Moichor serves veterinary clinics, animal hospitals, and diagnostic labs across the United States, addressing the need for more accessible, cost-effective, and reliable diagnostics in veterinary care. The company leverages artificial intelligence, computer vision, and expert veterinary knowledge to improve diagnostic accuracy and workflow efficiency, thereby enhancing animal health outcomes and reducing costs[1][2][3][5].
Moichor was founded in 2019 by Shevy Karbasi (CEO), Matt Chen (COO), and Thanh Le (CTO), who met at Penn State University while studying biology and machine learning. Initially focused on human diagnostics, the founders pivoted to veterinary diagnostics after recognizing the significant challenges in avian and reptile bloodwork, which relied on outdated, subjective, and costly manual methods. Their breakthrough came with pioneering the first fully automated Complete Blood Count (CBC) for exotic animals in 2020. This innovation set the foundation for Moichor’s mission to democratize access to cutting-edge diagnostic tools for veterinarians nationwide[1][3].
Moichor rides the growing trend of AI integration in healthcare diagnostics, specifically within the veterinary sector, which has historically lagged behind human medicine in adopting advanced technologies. The timing is critical as demand rises for more efficient, accurate, and affordable animal healthcare solutions, driven by increasing pet ownership and the complexity of exotic animal care. Market forces such as the need for decentralized diagnostics, cost pressures on veterinary practices, and advances in AI and machine learning favor Moichor’s approach. By enabling in-clinic, AI-powered diagnostics, Moichor is influencing the broader ecosystem by setting new standards for veterinary care accessibility and precision, potentially disrupting traditional lab-dependent workflows[1][2][3].
Looking ahead, Moichor is poised to expand its diagnostic capabilities beyond hematology and cytology, leveraging its AI platform to cover more pathology areas and animal species. Trends such as telemedicine, personalized veterinary care, and AI-driven diagnostics will shape its growth trajectory. As Moichor scales, it may deepen its impact by integrating with veterinary practice management systems and expanding internationally. Its influence will likely grow as it continues to lower barriers to advanced diagnostics, empowering veterinarians to deliver better, faster care and improving animal health outcomes globally. Moichor’s journey exemplifies how AI can revolutionize specialized healthcare niches, starting with veterinary diagnostics and potentially inspiring broader innovation in animal health technology[3][5].
